Please login to the form below

Not currently logged in
Email:
Password:

PRV

This page shows the latest PRV news and features for those working in and with pharma, biotech and healthcare.

Sanofi pays $245m for FDA priority review voucher

Sanofi pays $245m for FDA priority review voucher

Sanofi pays $245m for FDA priority review voucher. PRV reduces review time from ten to six months. ... The French pharma major is paying small US drugmaker Retrophin $245m for the priority review voucher (PRV), awarded as an incentive for carrying out

Latest news

  • J&J files new resistant TB drug bedaquiline in US

    The PRV would allow J&J to request priority review for another of its marketing applications. ... J&J was the first company to make use of a PRV after being awarded one for the approval of its antimalarial treatment Coartem (artemether/lumefantrine) in

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy. ... Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv

  • Pharma deals in August 2015 Pharma deals in August 2015

    In 2012 the PRV programme was extended to include rare pediatric diseases and the emergence of trading in PRVs was noted in our last annual Deal Watch report. ... Keeping this trend, United Therapeutics has sold a PRV to AbbVie for a headline value of

  • Pharma deals in May 2015 Pharma deals in May 2015

    The paediatric PRV was issued when Cholbam was approved for the treatment of patients with peroxismal disorders. ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam [cholic acid] in bile acid disorders.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Introduced by the FDA in 2007, a PRV is an incentive for companies to invest in treatments for neglected tropical diseases. ... Selling PRVs is a relatively new area and so these two deals provide initial benchmarks, however it will be interesting to see

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics